| Cancer Control Research: Active Research Grant Portfolio: Abstracts
Quality of Life in Gynecologic Cancer Survivors
Lari Wenzel, PhD
The gynecologic malignancy survivor cohort is the largest population of
long-term female survivors of all cancer sites, with early-stage ovarian
and endometrial cases comprising the majority of these survivors. To date,
however, long-term quality of life (QOL) disruptions and survivorship
concerns within this cohort remain unknown, despite the prevalence of
these cancers, as well as the great potential for cure for those with
early-stage disease. We propose to enhance development of a gynecologic
malignancy survivorship model through evaluation of quality of life (QOL)
concerns and survivorship sequelae of women who are long-term early stage
ovarian and endometrial cancer survivors. In addition, we propose to examine
potential QOL differences for endometrial cancer clinical trial survivors.
The study population will include early stage ovarian or endometrial cancer
survivors who completed participation in Gynecology Oncology Group (GOG)
clinical trial #95 (ovarian) or GOG clinical trial #99 (endometrial) at
least five years ago and are without recurrent disease. To achieve our
proposed study goals, we will utilize the GOG database for subject
identification and recruitment. A one-hour telephone assessment will occur
through the established Computer Assisted Telephone Interviewing (CATI) Unit
at AMC Cancer Research Center. The specific aims of the study include the
following: 1) to describe the significant quality of life concerns and
long-term survivorship issues of women who were diagnosed and treated for
early-stage ovarian or endometrial cancer five or more years ago, 2) to
identify mechanisms which contribute to a gynecologic cancer survivorship
model through comparison and prediction of high versus low quality of life
associated with long-term adjustment and survivorship, and 3) to identify
and compare factors which predict high versus low quality of life for
women with early-stage endometrial cancer who completed participation in
GOG clinical trial #99. Results from this study could significantly
contribute to future survivorship interventions and influence the direction
of care for patients with these cancers.
Back to the research index
|
